Brussels Stock Exchange:BCART

<!-- Name:DistributionId Value:1000784458 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4533 -->…

<!-- Name:DistributionId Value:1000782956 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4533 -->…

PRESS RELEASE:  REGULATED INFORMATION17 January 2023, 17:40 CET BIOCARTIS MEETS 2022 KEY OBJECTIVES Mechelen, Belgium, 17 January 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company…

PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen, Belgium, 16 January 2023 –Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular…

PRESS RELEASE: REGULATED INFORMATION16 December 2022, 17:40 CET Completion of Mandatory Conversion Capitalized terms not otherwise defined in this notice shall have the meaning given to them in the Terms and Conditions of the Bonds.…

PRESS RELEASE: REGULATED INFORMATION                                                                                9 December 2022, 17:40 CET Disclosure of transparency notifications Mechelen, Belgium, 9 December 2022 – Biocartis…

PRESS RELEASE: REGULATED INFORMATION                                                                                2 December 2022, 17:45 CET Disclosure of a transparency notification Mechelen, Belgium, 2 December 2022 – Biocartis…

PRESS RELEASE: REGULATED INFORMATION30 November 2022, 07:00 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 November 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics…

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 29 November 2022, 10:30 CET Biocartis Announces 55.91% of Offered Shares Subscribed at Closing of the Rights Subscription Period for Holders of Preferential Rights, and Start…

ADVERTISEMENT PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 16 November 2022, 07:00 CET Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of…